IP Verse

Preservative Free Bimatoprost And Timolol Solutions - EP2598118

The patent EP2598118 was granted to Allergan on Sep 5, 2018. The application was originally filed on Jul 28, 2011 under application number EP11745860A. The patent is currently recorded with a legal status of "Revoked".

EP2598118

ALLERGAN
Application Number
EP11745860A
Filing Date
Jul 28, 2011
Status
Revoked
Apr 27, 2024
Grant Date
Sep 5, 2018
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (6)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

MAIWALDJun 5, 2019MAIWALDADMISSIBLE
ALFRED E TIEFENBACHERJun 4, 2019HAMM & WITTKOPPADMISSIBLE
BAUSCH HEALTH IRELANDJun 4, 2019MAIWALDADMISSIBLE
HGFJun 4, 2019HGFWITHDRAWN
WACHTERSHAUSER & HARTZ PATENTANWALTSPARTNERSCHAFT MBB BLODIGJun 4, 2019HARTZWITHDRAWN
STADA ARZNEIMITTELMay 29, 2019KRAUS & LEDERER PARTGMBBADMISSIBLE

Patent Citations (13) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONUS20020153043-
INTERNATIONAL-SEARCH-REPORTEP2127638
INTERNATIONAL-SEARCH-REPORTFR2918891
INTERNATIONAL-SEARCH-REPORTUS2004082660
INTERNATIONAL-SEARCH-REPORTWO02092098
INTERNATIONAL-SEARCH-REPORTWO2007042262
OPPOSITIONEP2127638
OPPOSITIONFR2918891
OPPOSITIONUS2003069286
OPPOSITIONUS2004082660
OPPOSITIONUS2010210720
OPPOSITIONWO02096432
OPPOSITIONWO9517152

Non-Patent Literature (NPL) Citations (37) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
OPPOSITION- Anonymous, "Ganfort 300 Mikrogramm/ml +5 mg/ml Augentropfen - Allergan ®", Rote Liste Service GmbH, (20090300), pages 1 - 4, XP055609233-
OPPOSITION- Anonymous, "Timoptic® 0.25 % and 0.5% (timolol maleate ophtalmic solution) in Ocudose® (dispenser)", Merck & Co., Inc., (20050700), pages 3 - 9, XP055609229-
OPPOSITION- Biopharmaceutics of Ocular Drug Delivery, (19930000), pages 28 - 42-
OPPOSITION- CHMP, "Ganfort 300 micrograms/ml + 5 mg/ml eye drops, solution", Annex I. Summary of product characteristics, (20061105), pages 1 - 26, XP055603681-
OPPOSITION- "Delivery of Drugs to the Eye by Topical Application", Progress in Retinal and Eye Research, vol. 15, no. 2, pages 583 - 620-
OPPOSITION- D.F. WOODWARD et al., "The Pharmacology of Bimatoprost (LumiganTM)", Survey of Ophthalmology, (20010000), vol. 45, page S337, XP055187907-
OPPOSITION- EMEA, "Scientific Discussion (Ganfort)", (20060000), pages 1 - 37, XP055629311-
OPPOSITION- EMEA Summary of Product Characteristics of Ganfort, URL: https://www.ema.europa.eu/en/medicines/human/EPAR/ganfort-
OPPOSITION- Experimental report filed by patentee during examination proceedings;-
OPPOSITION- "Eye preparations", European Pharmacopoeia 4th edition, (20010000), page 539, XP055629302-
OPPOSITION- "Ganfor®t Eye drops", Allergan Pharmaceuticals, (20091009), XP055629299-
OPPOSITION- "GANFORT@ PF 0.3/5 eye drops", (20131113), pages 1 - 15, XP055629239-
OPPOSITION- GOLDBERG et al., Br. J. Ophthalmol., (20140700), vol. 98, no. 7, pages 926 - 31-
OPPOSITION- Handbook of Pharmaceutical Excipients, (20030000), pages 556 - 559-
OPPOSITION- Handbook of Pharmaceutical Excipients, (20030000), pages 574 - 576-
OPPOSITION- M. B. ABELSON, "The Secret World of Pharmacokinetics: Knowing something about this area of research can help make you a better clinician", Review of Opthalmology, (20090220), XP002785821-
OPPOSITION- "Ophthalmic preparation characteristics", Joseph P Remington; Alfonso R Gennaro, Remington: The science and practice of pharmacy. 20th ed., Lippincott Willians & Wilkings, (20000000), page 829, XP055603675-
OPPOSITION- "Ophthalmic Preparation Characteristics", Paul Beringer et al.,, Remington The Science and Practice of Pharmacy 21st Edition, Lippincott williams & Wilkins, (20050000), pages 861 - 862, XP055609231-
OPPOSITION- "Opthalmic preparations", Remington, The science and Practice of Pharmacy, (20000000), page 829, XP055629000-
OPPOSITION- "PRESERVATIVE-FREE STERILE OPHTHALMIC SOLUTION in a Sterile Ophthalmic Unit Dose Dispenser TIMOPTIC® 0.25% AND 0.5% (TIMOLOL MALEATE OPHTHALMIC SOLUTION) in OCUDOSE® (DISPENSER)", Merck & Co, (20050700), pages 1 - 7, XP055629309-
OPPOSITION- Product leaflet of Ganfort@, (20160900), XP002785821-
OPPOSITION- R. A. LAIBOVITZ et al., "Comparison of the Ocular Hypotensive Lipid AGN 192024 With Timolol", Arch Ophthalmol., (20010000), vol. 119, no. 7, pages 994 - 1000, XP001094959-
OPPOSITION- R. A. LEWIS et al., "Travoprost 0.004% With and Without Benzalkonium Chloride: A comparison of Safety and Efficacy", J. Glaucoma, (20070000), vol. 16, no. 1, pages 98 - 103, XP055462693-
OPPOSITION- Remington, The Science and Practice of Pharmacy, (20000000), pages 827 - 832-
OPPOSITION- The European Agency For The Evaluation Of Medicinal Products Human Medicines Evaluation Unit, "Note for Guidance on Inclusion of Antioxidants and Antimicrobial Preservatives in Medicinal Products", EMEA Note CPMP/CVMP/QWP/115/95, (19970708), pages 1 - 4, XP055609240-
OPPOSITION- "Timoptic® 0.25% and 0.5%", Aton Pharma, (20090200), pages 4 - 14, XP055628999-
OPPOSITION- CHRIS DE JONG et al., "Topical timolol with and without benzalkonium chloride: epithelial permeability and autofluorescence of the cornea in glaucoma", Graefe's Arch. Clin. Exp. Ophthalmol., (19940000), vol. 232, pages 221 - 224, XP055629307
OPPOSITION- G. RENIERI et al., "Efficacy and Tolerability of Preservative-Free Eye Drops Containing a Fixed Combination of Dorzolamide and Timolol in Glaucoma Patients", Journal of Ocular Pharmacology and Therapeutics, (20100000), vol. 26, no. 6, pages 597 - 603, XP055629222
OPPOSITION- C. BAUDOUIN, "Detrimental effect of preservatives in eyedrops: implications for the treatment of glaucoma", Acta Ophthalmologica, (20080000), vol. 86, pages 716 - 726, XP055603673
OPPOSITION- C. BAUDOUIN, "Detrimental effect of preservatives in eyedrops: implications for the treatment of glaucoma", Acta Ophthalmologica, (20081100), vol. 86, pages 716 - 726, XP055603673
OPPOSITION- CHRISTOPHE BAUDOUIN, "Detrimental effect of preservatives in eyedrops: implications for the treatment of glaucoma", Acta Ophthalmologica 2008, (20080000), vol. 86, doi:10.1111/j.1755-3768.2008.01250.x, pages 716 - 726, XP055603673
OPPOSITION- M. Q. RAHMAN et al., "Microbial contamination of preservative free eye drops in multiple application containers", Br. J. Ophthalmol., (20060000), vol. 90, pages 139 - 141, XP055629219
OPPOSITION- P. J. PISELLA et al., "Prevalence of ocular symptoms and signs with preserved and preservative free glaucoma medication", British Journal of Ophthalmology, (20020000), vol. 86, pages 418 - 423, XP055629318
OPPOSITION- I. GOLDBERG et al., "Bimatoprost 0.03%/timolol 0.5% preservative-free ophthalmic solution versus bimatoprost 0.03%/timolol 0.5% ophthalmic solution (Ganfort) for glaucoma or ocular hypertension: a 12-week randomised controlled trial", Br. J. Ophthalmol., (20140000), vol. 98, pages 926 - 931, XP055603671
OPPOSITION- I. GOLDBERG et al., "Bimatoprost 0.03%/timolol 0.5% preservative-free ophthalmic solution versus bimatoprost 0.03%/timolol 0.5% ophthalmic solution (Ganfort) for glaucoma or ocular hypertension: a 12-week randomised controlled trial", Br. J. Ophthalmol, (20140700), vol. 98, no. 7, pages 926 - 931, XP055603671
OPPOSITION- IVAN GOLDBERG et al., "Bimatoprost 0.03%/timolol 0.5% preservative-free ophthalmic solution versus bimatoprost 0.03%/timolol 0.5% ophthalmic solution (Ganfort) for glaucoma or ocular hypertension: a 12-week randomised controlled trial", British Journal of Ophthalmology 2014, (20140325), pages 926 - 931, XP055603671
OPPOSITION- CHRISTOPHE BAUDOUIN et al., "In vitro studies of Antiglaucomatous Prostaglandin Analogues: Travoprost with and without Benzalkonium Chloride and Preserved Latanoprost", Invest. Ophthalmol. Vis. Sci., (20070000), vol. 48, doi:10.1167/IOVS.07-0266, pages 4123 - 4128, XP002607568

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents